LCM
MYGN icon

Legato Capital Management’s Myriad Genetics MYGN Stock Holding History

Legato Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34,955
Closed -$479K – 604
2024
Q4 		$479K Sell
34,955
-10,961
-24% -$202K 0.06% 444
2024
Q3 		$1.26M Hold
45,916
– – 0.16% 232
2024
Q2 		$1.12M Buy
+45,916
New +$1.01M 0.15% 225

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Legato Capital Management's MYGN Position: Q1 2025 in Review

Legato Capital Management sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 34,955 shares — an estimated $479K sold.

Legato Capital Management first reported a position in MYGN in Q2 2024 and held it in 3 quarters. The position peaked at $1.26M in Q3 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

  • Legato Capital Management reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
  • Legato Capital Management sold 34,955 Myriad Genetics shares in Q1 2025, an estimated $479K.
  • Legato Capital Management first reported a position in Myriad Genetics in Q2 2024 and held it in 3 quarters.
  • Legato Capital Management's Myriad Genetics position peaked at $1.26M in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Legato Capital Management's 13F filing for Q1 2025, filed 6 May 2025.